| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200652 | Ophthalmology | 2015 | 8 Pages |
Abstract
Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment. No new safety concerns occurred with treatment. Intravitreal aflibercept should be considered as a treatment option for myopic CNV.
Keywords
CNVCrtBCVAChoroidal neovascularizationTEAEfluorescein angiographyOctbest-corrected visual acuityOptical coherence tomographyVisual acuitycentral retinal thicknessadverse eventtreatment-emergent adverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)disc areaLeast squares
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Yasushi MD, Kyoko MD, Tien Yin MD, PhD, Jean-Francois MD, Robert MD, Tummy MPH, Brigitte MD, Friedrich MD, Oliver MD, Tatsuro MD, PhD, MYRROR Investigators MYRROR Investigators,